SEMA3B antisense RNA 1 (SEMA3B-AS1)

SEMA3B antisense RNA 1 (SEMA3B-AS1) is a long non-coding RNA transcribed antisense to the SEMA3B gene. It acts as a tumor suppressor in several cancer types, including colorectal carcinoma, gastric cancer, breast cancer, and glioblastoma, where its expression is frequently downregulated[1][2][3]. SEMA3B-AS1 exerts its function by promoting the transcription of SEMA3B via epigenetic mechanisms: specifically, it recruits EP300, leading to increased acetylation of H3K9 at the SEMA3B promoter, which boosts SEMA3B expression[1]. Through this regulation, SEMA3B-AS1 ultimately inhibits proliferation, migration, invasion, and angiogenesis of tumor cells. Additionally, SEMA3B-AS1 can act as a competing endogenous RNA (“sponge”) for certain microRNAs (e.g., miR-3940-3p, miR-195), modulating other tumor suppressive or cell cycle regulatory pathways[2][3]. Its loss is associated with more aggressive disease and worse prognosis, suggesting its utility as a diagnostic or prognostic biomarker and a potential therapeutic target in cancer interventions[1][3].

Other names

SEAS1SEMA3B-AS1 (head to head)

Acts as an epigenetic regulator by recruiting the histone acetyltransferase EP300 to the SEMA3B promoter, increasing H3K9 acetylation, and boosting SEMA3B transcription[1] Functions as a molecular “sponge” for microRNAs such as miR-3940-3p, modulating downstream gene expression[3] Positive upstream regulator for miR-195, linking to the regulation of cyclin D1 and cell proliferation[2]